The 2.3% medical device tax could cost jobs and stymie the development of new products, Rep. Charles Boustany, R-La., said in testimony before the House Ways and Means Committee. In later comments to reporters, he said that efforts to repeal the levy may be considered "in the context of fundamental tax reform," echoing comments previously made by the medtech industry.
House panel holds hearing on medical device tax repeal
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|